Barclays
ETTX

Barclays’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Barclays’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-112
Closed – – 5156
2021
Q1 		$0 Buy
+112
New +$318 ﹤0.01% 5346

Other funds holding ETTX

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Barclays's ETTX Position: Q2 2021 in Review

Barclays sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q2 2021, closing a stake of 112 shares.

Barclays first reported a position in ETTX in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 24 funds tracked by Wall St. Rank hold ETTX as of Q2 2021.

  • Barclays reported no remaining Entasis Therapeutics Holdings Inc. position as of Q2 2021 after selling out during the quarter.
  • Barclays sold 112 Entasis Therapeutics Holdings Inc. shares in Q2 2021.
  • Barclays first reported a position in Entasis Therapeutics Holdings Inc. in Q1 2021 and held it in 1 quarter.
  • Barclays's Entasis Therapeutics Holdings Inc. position peaked at $0 in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.